YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Major earnings expected before the bell on Monday include: * Kandi Technologies Group (KNDI [https://seekingalpha.com/symbol/KNDI]) * Palatin Technologies (PTN [https://seekingalpha.com/symbol/PTN]) * For Seeking Alpha's full earnings seas…
Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired hypothalamic obesity and Bardet-Biedl syndr…
Palatin Techs (AMEX:PTN) held its third-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://ww…
* Palatin Technologies press release [https://seekingalpha.com/pr/20512993-palatin-reports-fiscal-third-quarter-2026-financial-results-and-provides-business-update] (PTN [https://seekingalpha.com/symbol/PTN]): Q3 GAAP EPS of -$0.37. * The…
There's a growth stock that has skyrocketed more than Google parent Alphabet(NASDAQ: GOOG)(NASDAQ: GOOGL) and Nvidia(NASDAQ: NVDA) over the last 12 months. Wall Street loves this stock, with the consensus price target reflecting a potentia…
The Australian stock market is experiencing a slight dip, with shares expected to open 0.3% lower due to global economic factors such as new tariffs from the U.S. on Europe. Despite these challenges, there are still opportunities for inves…
Thinkstock Quick Read After a brutal Monday, investors were treated to a snap-back rally in stocks on Tuesday. All of the major indices and Cryptocurrencies finished the day higher on Tuesday as hopes for an interest rate cut remained posi…
The Australian market is facing a challenging period, with the ASX 200 futures indicating a significant drop following recent U.S. economic disruptions and domestic political shifts affecting investor sentiment. Despite these hurdles, oppo…
As Australian shares experience a slight dip following recent bullish activity, the market remains a dynamic landscape influenced by global factors such as gold prices and geopolitical events. In this context, identifying promising stocks…
In this article, we will take a detailed look at the 10 Micro-Cap Healthcare Stocks Insiders Are Buying. For a quick overview of such stocks, read our article5 Micro-Cap Healthcare Stocks Insiders Are Buying. Investors have always been int…
Palatin Technologies, Inc. (AMEX:PTN) Q2 2024 Earnings Call Transcript February 15, 2024 Palatin Technologies, Inc. misses on earnings expectations. Reported EPS is $-0.56 EPS, expectations were $-0.43. Palatin Technologies, Inc. isn’t one…
Vyleesi (Photo: Business Wire) Only FDA-Approved As-Needed Treatment For The Approximately 6 Million Premenopausal Women Who Suffer From Hypoactive Sexual Desire Disorder (HSDD) Vyleesi® has experienced 8 Consecutive Quarters of Double-Dig…
Palatin Technologies, Inc. (AMEX:PTN) Q1 2024 Earnings Call Transcript November 14, 2023 Operator: Greetings. Welcome to Palatin’s First Quarter Fiscal Year 2024 Operating Results Conference Call. At this time, all participants are in a li…
Palatin Technologies, Inc. (AMEX:PTN) Q4 2023 Earnings Call Transcript September 29, 2023 Operator: Greetings, and welcome to Palatin's Fourth Quarter and Fiscal Year End 2023 Operating Results Conference Call. At this time, all participan…
CRANBURY, N.J., Aug. 4, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system…
$4.1 million in Gross Product Revenue $1.7 million in Net Product Revenue 14% growth in prescriptions dispensed over 3Q23; 89% growth over 4Q22 20% growth in new healthcare prescribers over 3Q23 CRANBURY, N.J., July 11, 2023 /PRNewswire/ -…
– Results demonstrate melanocortin agonists may represent a new therapeutic avenue to treat diabetic nephropathy – Open Label Phase 2 clinical study in diabetic kidney disease enrolling patients CRANBURY, N.J., May 30, 2023 /PRNewswire/ --…
Palatin Technologies, Inc. (AMEX:PTN) Q3 2023 Earnings Call Transcript May 16, 2023 Palatin Technologies, Inc. misses on earnings expectations. Reported EPS is $-0.75 EPS, expectations were $-0.39. Operator: Greetings. Welcome to Palatin’s…
Participants Carl Spana; Co-Founder, President, CEO & Director; Palatin Technologies, Inc. Stephen T. Wills; CFO, COO, Executive VP, Treasurer & Secretary; Palatin Technologies, Inc. Joseph Pantginis; Director of Research & MD of Equity Re…
Palatin Technologies, Inc. (PTN) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.75 per share a year ago. These figures are adjusted for non-recurring it…
Phase 3 PL9643 Data in Patients with Dry Eye Disease Presented at KOL Event Phase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis Vyleesi® Received $4.7 Million of Non-Dilutive Funding Through NJ Economic Development Pr…
Alimera Sciences (ALIM) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.85 per share a year ago. These figures are adjusted for non-recurring items. This…
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.75 per share a year ago. These figures are adjusted for non-recurring items. This q…
CRANBURY, N.J., May 11, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2023 operating results on Tuesday, May 16, 2023, before the open of the U.S. financial markets. Palati…
Guardant Health (GH) came out with a quarterly loss of $1.30 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.21 per share a year ago. These figures are adjusted for non-recurring items. This qu…
– Preclinical data presented shows PL8177 was found to be efficacious in animal models of inflammatory bowel disease – Clinical data confirms PL8177 oral formulation is delivered and contained in the colon – Phase 2 clinical study data rea…
CRANBURY, N.J., May 8, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system,…
- Review of Phase 3 PL9643 Data for Dry Eye Disease - Data demonstrates PL9643 positive effects on signs and symptoms of dry eye disease - Webinar to take place on Monday, May 8, 2023 at 11:00 AM ET CRANBURY, N.J., May 1, 2023 /PRNewswire/…
- Poster data demonstrates PL9643 positive effects on signs and symptoms of dry eye disease - Consistent clinical efficacy across multiple signs and symptoms of dry eye along with excellent safety and tolerability build a differentiating p…
- Poster presented at ARVO demonstrates PL9588 reduces intraocular pressure - Data provides further support for topical administration of melanocortins for ocular inflammation CRANBURY, N.J., April 25, 2023 /PRNewswire/ -- Palatin Technolo…
$3.4 million in Gross Product Revenue $1.2 million in Net Product Revenue 27% growth in prescriptions dispensed over 2Q23; 147% growth over 3Q22 CRANBURY, N.J., April 19, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN)…
- International Journal of Molecular Sciences manuscript demonstrates robust pre-clinical data in two retinal disease models - Studies further demonstrate broad utility of melanocortin agonists in treating inflammatory conditions, especial…
Oral PL8177 is gut restricted in rats, dogs and humans Bioinformatics data shows positive effects on enterocytes and infiltrating immune cells CRANBURY, N.J., March 2, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a…
CRANBURY, N.J., Feb. 28, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor syste…
Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Phase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis Commenced Phase 2 Clinical Study of Bremelanotide in Patients with Diabetic Kidney Disease V…
CRANBURY, N.J., Feb. 10, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2023 operating results on Wednesday, February 15, 2023, before the open of the U.S. financial market…